Laxabon (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macrogol 3)

Polyethylene glycol in Laxabon creates an osmotic gradient that draws water into the intestinal lumen. The retained water softens the stool and expands its volume, stimulating peristalsis and facilitating the passage of feces without being absorbed into the bloodstream.

The appropriate dose of Laxabon is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of constipation, and clinical response. Patients should follow the prescriber’s instructions and not adjust the volume on their own.

Safety data for Laxabon in pregnancy and lactation are limited. Healthcare providers usually weigh the benefits against potential risks before prescribing. Women who are pregnant or breastfeeding should discuss use with their physician to determine if it is appropriate for their situation.

To order Laxabon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with stimulant laxatives, Laxabon (polyethylene glycol) works locally without stimulating intestinal nerves, resulting in a gentler, more physiologic effect. Unlike bulk‑forming agents, it does not rely on fiber intake. Its electrolyte formulation helps maintain fluid balance, making it suitable for patients needing controlled osmotic action.

Laxabon should be stored at ambient temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and store it in its original packaging to preserve stability and potency.

Laxabon is taken orally as a measured liquid solution. The prescribed volume is mixed with a suitable amount of water or other clear fluid, shaken gently if needed, and consumed according to the healthcare provider’s directions, usually once daily or as instructed.

Serious risks include severe electrolyte imbalance (such as hyponatremia or hypokalemia), marked dehydration, and rare allergic reactions that may present as rash, swelling, or anaphylaxis. Patients experiencing these symptoms should seek immediate medical attention.

Laxabon is contraindicated in individuals with known or suspected bowel obstruction, perforation, or severe inflammatory bowel disease. Patients with significant renal impairment, uncontrolled electrolyte disorders, or hypersensitivity to any component of the formulation should avoid its use.